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There is inter-individual variability in the responses to
anti-diabetic treatments, partly due to genetic factors
involved in drug absorption, distribution, metabolism
and target. The identification of genetic markers related
to drug reaction can help physicians with the decisions
of drug selection, dose titration, treatment duration, and
avoidance of advert drug reactions. We focused on the
effects of susceptibility genes for T2D on anti-diabetic
drugs’ efficacy. With respect to repaglinide, genetic var-
iants at multiple loci such as CYP2C8, SLCO1B1, KCNJ11,
TCF7L2 and SLC30A8, affect either its pharmacokinetics
or pharmacodynamics. We also made some efforts on
pharmacogenetic studies of repaglinide efficacy. We
recruited a total of 104 Chinese patients with type 2 dia-
betes and with no history of prior antidiabetic medica-
tions, to whom subsequent repaglinide monotherapy with
a 48-week follow-up was applied. Based on studies on this
cohort, genetic variations at KCNJ11, ABCC8, NOS1AP
and KCNQ1 were found to be associated with repaglinide
efficacy. Moreover, we also focused on investigations into
possible genetic factors for rosiglitazone efficacy, and have
already suggested effects of ABCA1 and SLC30A8 variants
on the response to rosiglitazone treatment. In spite of all
these advances in the field of pharmacogenetics of type 2
diabetes, the pace of clinical application of these findings
is rather slow. Consequently, more researches especially
randomized clinical trials into the practical utility should
be conducted.
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